NCT00789477View on ClinicalTrials.gov

DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact

PHASE2CompletedINTERVENTIONAL

Enrollment

221

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

September 30, 2010

Conditions

Diabetic Macular Edema

Interventions

PROCEDURE

Laser Photocoagulation

laser every 16 weeks as needed

DRUG

Intravitreal Aflibercept Injection

Trial Locations (47)

1090

Vienna

14620

Rochester

15213

Pittsburgh

21287

Baltimore

27607

Raleigh

28210

Charlotte

29169

West Columbia

29605

Greenville

30909

Augusta

33334

Fort Lauderdale

33410

Palm Beach Gardens

33426

Boynton Beach

33880

Winter Haven

33912

Fort Myers

34474

Ocala

37203

Nashville

45243

Cincinnati

46280

Indianapolis

48104

Jackson

64108

Kansas City

68506

Lincoln

76012

Arlington

77030

Houston

78215

San Antonio

78240

San Antonio

78503

McAllen

78705

Austin

79606

Abilene

84107

Salt Lake City

90211

Beverly Hills

90701

Artesia

91105

Pasadena

92705

Santa Ana

94040

Mountain View

95819

Sacramento

96815

Honolulu

06518

Hamden

06320

New London

04401

Bangor

02114

Boston

08901

New Brunswick

08225

Northfield

08753

Toms River

V5Z 3N9

Vancouver

V8V 4X3

Victoria

N6A 4G5

London

L4W 1W9

Mississauga

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY